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To the Editor:
The epidermal permeability barrier (PB) consists of two key
elements, the anuclear corneocytes (‘‘the bricks’’) and an
intercellular matrix (‘‘the mortar’’), the latter consisting pri-
marily of specialized non-polar lipids, predominantly ceram-
ides, cholesterol, and free fatty acids (reviewed in Elias et al,
1998; Nemes and Steinert, 1999; Madison, 2003). While the
role of the corneocyte and its associated cornified envelope
(CE) in mechanical defense and maintaining skin integrity is
well established, its role in PB function is less clear. It has
been suggested that one role of individual corneocytes in
the barrier is to serve as ‘‘spacers’’, which create an elon-
gated, tortuous diffusion pathway for exogenous com-
pounds to migrate through (Potts and Francoeur, 1990).
More recently, it has been proposed that the CE is required
for the supramolecular organization of the extracellular
matrix into elongated lamellar bilayers (Downing, 1992;
Elias et al, 2002b). This is consistent with recent biochem-
ical studies demonstrating a close molecular association
between CE components such as involucrin and the o-hy-
droxyceramides of the lipid envelope (Wertz et al, 1989;
Marekov and Steinert, 1998; Nemes et al, 1999).
Acute disruption of the murine epidermal barrier is ac-
companied by a short-term loss of Ca2þ from the outer
epidermis and a rapid secretion of preformed lamellar bod-
ies (LB) within 15–30 min. LBs continue to be hypersecreted
for at least 6 h after acute barrier perturbations, coinciding
with a reduction in transepidermal water loss (TEWL) to-
wards pre-disruption levels (Menon et al, 1992; Menon et al,
1994; Elias et al, 1998). Disruption of the normal Ca2þ gra-
dient also results in reduced levels of profilaggrin and
loricrin mRNAs at 3–24 h, probably reflecting their regulation
via the Ca2þ -dependent protein kinase C pathway (Dlugosz
and Yuspa, 1993; Elias et al, 2002a). Levels of CE proteins
appear to be largely unaffected, however, presumably re-
flecting their long half-lives in vivo. Other studies have sug-
gested that the levels of some CE proteins, notably K1, K10,
and involucrin, increase during barrier repair (Ekanayake-
Mudiyanselage et al, 1998).
Therefore, based on the limited available evidence, over-
expression (transgenic) models involving CE or structural
epidermal proteins could have either negative or positive
consequences for PB function. Elevated levels of structural
proteins could interfere with barrier recovery by congesting
the cytosol, as demonstrated in chromaffin cells of the ad-
renal medulla where a highly organized actin cytoskeleton
regulates catecholamine release by entrapping secretory
granules, preventing their exocytosis in unstimulated cells
(Aunis and Bader, 1988). A similar paradigm may occur in
epidermolytic hyperkeratosis (EHK) patients which have a
severe barrier defect in concert with collapsed, disorgan-
ized keratin filaments (Schmuth et al, 2001). In EHK pa-
tients, LBs are incompletely secreted and their lipid con-
tents partially entombed within corneocytes, perhaps as a
result of a congested cytoplasm. Alternatively, excess pro-
tein levels could enhance PB function and recovery by pro-
viding a superior CE scaffold. A third possibility arising from
overexpression of a structural protein is that the balance
between the individual constituents in corneocytes might be
altered, which might have an effect on barrier recovery.
To determine how structural/CE protein expression influ-
ences PB function, we studied three well-characterized
transgenic models overexpressing the differentiation-spe-
cific proteins K16 (Takahashi et al, 1994; Coulombe et al,
1995), involucrin (Crish et al, 1993), and filaggrin (this paper).
We tested the hypothesis that overexpression of these ep-
idermal proteins, with (in the case of K16) or without (in the
case of involucrin and filaggrin) attendant cytoskeletal ker-
atin filament disruption would affect permeability barrier
function in different ways. All animal protocols were ap-
proved by the Institutional Animal Care and Use Commit-
tees at the respective institutions.
The preparation and characterization of the K16 and in-
volucrin transgenic models have been described previously.
Both of these transgenic models express the transgene in
the suprabasal epidermis (as well as the hair follicle) using
the native promoter, but at markedly elevated levels as a
function of increased copy number and breeding to ho-
mozygosity. K16 transgenic mice, line 5–7 (Takahashi et al,
1994), display skin lesions that are first observed as hype-
rkeratinization of the outer root sheath (ORS) in hair follicles,
starting during the first week post partum. Because the
ORS is contiguous with the interfollicular epidermis, and
because K16 gene expression is strongly inducible upon
‘‘disease’’, the local hyperproliferation and thickening of the
ORS spreads to the adjacent epidermis surrounding hair
follicles. In the surrounding interfollicular epidermis, dys-
keratosis, acanthosis, acantholysis, and hyperkeratosis are
all apparent; in addition, there is keratin filament disorgan-
ization (often collapsed, in a perinuclear pattern) and re-
duced desmosome density at the cell surface (Takahashi
et al, 1994; Coulombe et al, 1995). Human K16 is over-
expressed 3–5-fold relative to endogenous mouse K16
(Coulombe et al, 1995). Involucrin transgenic mice bred
to homozygosity express two or four times the levels of
Abbreviations: CE, cornified envelope; LB, lamellar bodies; PB,
permeability barrier; TEWL, transepidermal water loss
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involucrin seen in control mice, and exhibit a scaly epider-
mis in neonates with a diffuse alopecia; however, in contrast
to the K16 mice, there was no evidence of hyperplasia or
hyperkeratosis (Crish et al, 1993).
The third transgenic model we studied expressed human
filaggrin using the human involucrin promoter (Carroll et al,
1993). In this transgenic model, we bypassed the normal
tight control over filaggrin production in the upper granular
and transition layers by expressing human filaggrin in the
spinous and granular layers, to determine if premature ex-
pression of filaggrin (and aggregation of keratin filaments)
would affect epidermal differentiation. These mice ex-
pressed mature filaggrin in the suprabasal layers, as dem-
onstrated by immunohistochemistry and by immunoblot
analysis with a human filaggrin-specific antibody (Fig 1).
There was little or no human filaggrin detected in the stra-
tum corneum, as determined by both immunohistochemis-
try and immunoelectron microscopy of transgenic skin.
Human filaggrin expression in transgenic mice bred to
homozygosity results in a 100%–150% increase in total
filaggrin synthesis over control animals, estimated from
Commassie-stained protein gels (data not shown).
In contrast to the other two models, no abnormalities in
epidermal or hair follicle structure or tissue organization was
observed in filaggrin transgenic mice examined by histol-
ogy, electron microscopy, or immunohistochemistry (Fig 1,
and see figure legend). Notably, there was no evidence, ei-
ther by light or electron microscopy, of altered keratin fil-
ament organization in the suprabasal layers of transgenic
epidermis. One possible mechanism to account for the
absence of keratin filament disruption in the spinous and
granular layers of filaggrin transgenics was that the human
filaggrin was phosphorylated, which would prevent it from
interacting with keratins (Harding and Scott, 1983). We
checked for this possibility by injection of 32P-orthophos-
phate into newborn transgenic mice, which has been shown
to efficiently label mouse profilaggrin (Harding and Scott,
1983; Pearton et al, 2002). We observed no labeling of the
transgenic human filaggrin or mouse filaggrin, while mouse
profilaggrin was strongly labeled, as expected (data not
shown). A second possibility is that the transgenic human
filaggrin is somehow prevented from binding to, and ag-
gregating keratins, even though it is present in the cytosol of
spinous and granular cells. This form of human filaggrin ef-
ficiently aggregates keratin filaments when expressed
in vitro, however, either in rat keratinocytes (K5/K14 and
K1/K10 filaments) or monkey COS-7 cells (K8/K18 fila-
ments) (Dale et al, 1997; Presland et al, 2001). In addition,
there is disruption of cell–cell adhesion in keratinocytes
overexpressing filaggrin (Presland et al, 2001), which we did
not observe in mice. We suggest that cultured cells may be
more sensitive to keratin filament disruption than epidermal
tissue, which express a greater diversity of keratin proteins
and thus contain a more robust intermediate filament net-
work with stronger cell–cell adhesion via desmosomes.
In order to determine if elevated expression of these
structural proteins, i.e., K16, involucrin, and filaggrin can
influence PB function, TEWL was measured in both the
basal (unperturbed) state and after tape stripping of shaved
mouse skin. For all three transgenic models, baseline TEWL
values did not vary significantly between transgenic and
Figure1
Characterization of transgenic mice expressing human filaggrin in
the suprabasal layers. Construction of the human filaggrin transgene
is described elsewhere (Dale et al, 1997). The protein expressed in mice
was a single human filaggrin unit (a cDNA encoding a protein of 314
amino acids) cloned into the plasmid H3700-pL2, which contains the
human involucrin promoter (gift of Dr J. Carroll, Genetics Institute, An-
dover, Massachusetts) (Carroll and Taichman, 1992; Carroll et al, 1993).
Homozygous mice from line 7781 that expressed human filaggrin
(strain C57BL/6J  SJL/J; HUGO designation Tg (FLG) 7781Pres) was
used for all the studies reported here. No gross abnormalities were
observed in the structure of skin or hair in newborn or adult transgenic
mice from either line. (A) Immunoblot analysis of epidermis with human
filaggrin-specific antibody. Shown are urea/Tris protein extracts of two
transgenic (lanes 1, 2) and non-transgenic littermates (lanes 3, 4) of F2
generation mice from line 7781 blotted with filaggrin antibody 8959
(Fleckman et al, 1985). Lane F is a human epidermal foreskin extract to
indicate the size of human filaggrin (hFG, 37 kDa). M, molecular weight
markers. Molecular sizes of protein standards (in kDa) are indicated at
left. (B) Suprabasal expression of human filaggrin in transgenic mice.
Dorsal skin from control (A, C) or transgenic (B, D) mice were stained
with hematoxylin–eosin (A, B) or immunostained with human filaggrin
antibody 8959 (C, D). Expression is confined to the suprabasal spinous
and granular layers (D), as expected using the involucrin promoter. Note
that transgenic mouse epidermis shows normal thickness and cellular
organization (B). Electron microscopy of transgenic mouse epidermis,
performed as described previously (Presland et al, 1997), demonstrat-
ed (a) the presence of keratohyalin granules that were normal both in
appearance and number and (b) cytoplasmic keratin filaments in upper
epidermal layers were normally organized (data not shown).
Immunohistochemical studies, performed with a panel of antibodies
specific for mouse K14, K1, K6, and K10, profilaggrin, loricrin, and
involucrin demonstrated no measurable alterations in expression of
differentiation markers (not shown). hFG, human filaggrin. Scale
bar¼30 mm.
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control (non-transgenic) groups derived from the same
breeding line. The baseline TEWL values (in mg per cm2 per
h) were as follows: K16 transgenics (n¼ 4), 12.0  1.4; K16
controls (n¼ 4), 12.5  0.96; involucrin transgenics, (n¼ 4)
13.0  0.6; involucrin controls (n¼4), 11.5  1.0; filaggrin
transgenics (n¼5), 12.4  0.68; filaggrin controls (n¼ 5),
12.6  1.08. Next, we assessed barrier recovery in all three
overexpressing models, measured at 3 and 6 h after acute
barrier disruption. The results demonstrate that while there
was no alteration in barrier recovery kinetics with the in-
volucrin mice compared to control (non-transgenic) ani-
mals, there was in the K16 and filaggrin mice (Fig 2). In the
K16 mice, a significant (  2-fold) delay in barrier recovery
was observed at 3 h after tape stripping (po0.02), which
was still seen at 6 h although it was no longer statistically
significant (Fig 2). In contrast, filaggrin transgenic mice
showed significantly accelerated barrier recovery kinetics
(po0.05 at 3 h; Fig 2). These studies demonstrate that el-
evated (in the case of K16) or premature (in the case of
filaggrin) expression of these cytoskeletal differentiation-
specific proteins results in a significant delay and acceler-
ation in barrier recovery, respectively. The three groups of
control mice exhibited considerable variation in recovery
rates (Fig 2). TEWL rates vary significantly from strain-to-
strain, and can vary even within a strain as a function of
stress levels (Elias and Feingold, unpublished). In this study,
not only are the control and transgenic mice for each group
of the same genetic background, but the wild-type controls
were always studied at the same time and under identical
conditions as the transgenic animals. Therefore, the differ-
ences in TEWL rates between control and transgenic mice
are not due to strain differences but, directly or indirectly,
due to the expressed transgene.
What do these results tell us about the role of structural
proteins in the maintenance and repair of the epidermal PB?
Maintenance of barrier homeostasis requires the outermost
granular cell to rapidly deliver preformed and newly syn-
thesized lipids and enzymes (packaged in LBs) to the inter-
cellular spaces of the stratum corneum. Certain structural
specializations, such as a widely deployed trans-Golgi net-
work, compound exocytosis, and deep invaginations of the
apical plasma membrane, facilitate this process (Elias et al,
1998). Among the phenotypic changes seen in K16
transgenics is a reorganized keratin filament network which
is often collapsed near or around the nucleus, and reduced
numbers of desmosomal cell–cell junctions associated with
acantholysis (Takahashi et al, 1994; Coulombe et al, 1995).
The disrupted keratin cytoskeleton and desmosomal
changes could both account for the delay in barrier recov-
ery, by disrupting the normal secretion of LBs in a manner
similar to that seen in the skin disease EHK where there is
both a congested cytosol (due to keratin filament collapse)
and aberrant secretion of LBs in the granular layer (Schmuth
et al, 2001). In the K16 mice, there is also reduced expres-
sion of differentiation markers (K10, filaggrin) and upregu-
lation of some other hyperproliferation-associated proteins
(K6, K17), all of which may impact the efficiency of barrier
repair (Takahashi et al, 1994). In the filaggrin transgenic
mice, there was a significant improvement in the rate of
barrier repair (Fig 2). By all criteria measured, these mice
were phenotypically normal, and there were no alterations in
keratin filament organization or the expression of differen-
tiation markers (including endogenous profilaggrin expres-
sion and processing to filaggrin in the upper granular layer).
The fact that the transgenic human filaggrin is restricted
primarily to the living epidermal layers suggests that its
beneficial effect on PB repair does not involve altering the
composition of ‘‘natural moisturizing factor’’ in cornified
cells (Rawlings et al, 1994), but rather by affecting repair
events in the differentiating layers such as LB secretion or
the functioning of the epidermal CE.
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Figure2
Barrier recovery in transgenic mouse models measured at varying
times after acute barrier disruption. 6–8-wk-old mice were shaved
24 h prior to study and permeability barrier disruption was performed
by repeated, sequential cellophane tape stripping of the same sites on
the dorsal flanks, until TEWL exceeded 2 mg per cm2 per h (Elias et al,
2002a; Hachem et al, 2003). TEWL was assessed with an electrolytic
water analyzer (Meeco, Warrington, Pennsylvania) immediately after
barrier abrogation, and at 3 and 6 h following disruption, in a temper-
ature and humidity-controlled room (temperature and relative humidity
were maintained at 221C  21C and 60%  5%, respectively). Meas-
urements were taken from three adjacent sites, and data for each an-
imal in each group represent the mean of three sites from one flank.
Non-transgenic mice of a similar age and from the same genetic back-
ground were used as controls and all measurements of control and
transgenic groups were performed simultaneously. Barrier recovery is
shown as percent recovery of TEWL to the normal, pre-disruption rate
in transgenic models versus wild-type littermates. po0.02 at 3 h in
K16 transgenic mice; po0.05 at 3 h in filaggrin transgenic mice,
assessed using a two-tailed Student’s t test. Data are expressed as
mean  SEM. Number of animals studied were: Involucrin transgenic,
n¼ 7; involucrin control, n¼8; K16 transgenic, n¼ 15; K16 control,
n¼ 21; filaggrin transgenic, n¼ 16; filaggrin control, n¼ 11.
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